~~<i id='ACED4EE3CB'><strike id='ACED4EE3CB'><tt id='ACED4EE3CB'><pre id='ACED4EE3CB'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：knowledge 2025-09-06 06:05:33 Page View：9921

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood
Next article： Peter Hotez and the public health issue of online harassment

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

American taxpayers paid $1.8 trillion in health care costs in 2022

AdobeAmericantaxpayersfootedthebillforatleast$1.8trillioninfederalandstatehealthcareexpendituresin20

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Johnson & Johnson sues to stop Medicare negotiation

MARKRALSTON/AFPviaGettyImagesWASHINGTON— PharmaceuticalgiantJohnson&JohnsononTuesdaybecamethethi